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Objectives: Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single
nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the
constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver, and a
CAR polymorphism (rs2307424) and smoking correlate with efavirenz plasma concentrations, we investigated
their association with early (,3 months) discontinuation of efavirenz therapy.
Methods: Three hundred and seventy-three patients initiating therapy with an efavirenz-based regimen were
included (278 white patients and 95 black patients; 293 male). DNA was extracted from whole blood and
genotyping for CYP2B6 (516GT, rs3745274), CAR (540CT, rs2307424) and PXR (44477TC, rs1523130;
63396CT, rs2472677; and 69789AG, rs763645) was conducted. Binary logistic regression using the back-
wards method was employed to assess the influence of SNPs and demographics on early discontinuation.
Results: Of the 373 patients, 131 withdrew from therapy within the first 3 months. Black ethnicity [odds ratio
(OR)¼0.27; P¼0.0001], CYP2B6 516TT (OR¼2.81; P¼0.006), CAR rs2307424 CC (OR¼1.92; P¼0.007) and
smoking status (OR¼0.45; P¼0.002) were associated with discontinuation within 3 months.
Conclusions: These data indicate that genetic variability in CYP2B6 and CAR contributes to early treatment
discontinuation for efavirenz-based antiretroviral regimens. Further studies are now required to define the
clinical utility of these associations.
Keywords: pharmacogenetics, pharmacokinetics, metabolism, drug disposition
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Introduction
Efavirenz treatment is associated with CNS or neuropsychiatric
side effects in a large proportion of patients (25%–70%), and
can give symptoms such as dizziness, headache, abnormal
dreams and sleep disturbance, mood changes, anxiety, dizziness,
and impaired concentration.1 – 3 CNS side effects normally arise in
the first days/weeks of treatment and for a small minority of
patients can be prolonged for several months or emerge after
numerous weeks of treatment,4 but do not always result in dis-
continuation of therapy. Discontinuation of efavirenz-containing
regimens has been reported with various frequencies in different
studies, ranging from 5% to 20%, and neuropsychiatric side
effects account for the majority of discontinuation cases.3,5 – 7
The causes of CNS and other side effects related to efavirenz-
containing regimens have not been fully characterized, but
some studies indicate that neuropsychiatric side effects are
associated with high plasma concentrations, particularly in the
first weeks of treatment.8 – 10
Phase I metabolism of efavirenz is predominantly catalysed by
cytochrome P450 2B6 (CYP2B6), and single nucleotide polymorph-
isms (SNPs) within the CYP2B6 gene are associated with altered
hepatic CYP2B6 expression and activity.11 The role of the
516GT (rs3745274) SNP in the pharmacokinetics of efavirenz
has been studied extensively.12 – 19 In addition to CYP2B6, a sec-
ondary route of phase I metabolism of efavirenz is catalysed by
CYP2A6 and CYP2A6 polymorphisms have also recently been ident-
ified as determinants of efavirenz plasma concentrations.20 – 23
The primary metabolite of phase I metabolism, 8-hydroxy
efavirenz, then undergoes glucuronidation prior to excretion in
the urine and bile. This phase II metabolism has recently
been attributed to UDP-glucuronosyltransferase isoform 2B7
(UGT2B7)24 and evidence is emerging that UGT2B7 polymorph-
isms are also associated with efavirenz plasma concentrations.20
Hence, a thorough knowledge of the routes of metabolism and
elimination of efavirenz have successfully identified candidate
genes for pharmacogenetic studies.
The constitutive androstane receptor (CAR) and the pregnane
X receptor (PXR) are known to regulate a complex network of
phase I and phase II metabolic enzymes in response to xeno-
biotics. Importantly, CAR and PXR expression also correlate
with CYP2B625 and CYP2A626 expression in liver, even in the
absence of enzyme inducers and xenobiotics. Activators of CAR
have also been shown to induce UGT2B genes in vivo,27 and so
CAR appears to play a role in the basal and inducible regulation
of the enzymes involved in efavirenz metabolism.
Therefore, we hypothesized that interindividual variability in
CAR and PXR caused, for example, by polymorphisms, would
result in additional interindividual variability in CYP2B6, CYP2A6
and UGT2B7. Single nucleotide polymorphisms have been
reported in PXR28 and CAR29 genes, and we have previously
shown an association of a PXR SNP (63396CT, rs2472677)
with unboosted atazanavir plasma concentrations30 and an
association of a CAR SNP (540CT, rs2307424) with plasma
concentrations of efavirenz.31
The aim of this study was to investigate the association of
CYP2B6 (516GT, rs3745274), CYP2A6 (CYP2A6*9B, rs8192726),
UGT2B7 (735AG, rs28365062; and 802TC, rs7439366),
CAR (540CT, rs2307424) and PXR (44477TC, rs1523130;
63396CT, rs2472677; and 69789AG, rs763645)
polymorphisms with discontinuation within 3 months of initiating
efavirenz-containing regimens. In addition, the associations with
demographic factors, including ethnicity, smoking habits and
gender, were also investigated.
Patients and methods
Patients
A total of 373 patients who were on stable efavirenz-containing highly
active antiretroviral therapy (HAART) for ≥3 months (n¼242; control
group) or who discontinued efavirenz-containing HAART within
3 months (n¼131; early discontinuation group) were included in this
cohort study.
We included patients of the cohort of the German Competence
Network for HIV/AIDS (KompNet Cohort) with documented stable
efavirenz treatment for ≥3 months and compared with those who
discontinued efavirenz-containing HAART within 3 months. A further
inclusion criterion was the availability of already stored EDTA samples.
All concomitant medications were documented and patients were
excluded from the analysis if they received drugs with known drug
interactions. No patients were receiving anti-TB treatments.
Out of 480 patients with stable efavirenz-containing HAART identified
as a potential control group, stored EDTA samples were available from
255 patients. In 13 of these patients, genotyping for one or more SNP
was not successful. Therefore, 242 patients on stable therapy were
included in the final analysis. The median duration of efavirenz therapy
in this group was 48 months (range 5–99 months). Two hundred and
thirteen patients were identified with early discontinuation of efavirenz-
containing HAART, therefore fulfilling the inclusion criteria. In 131
patients, EDTA samples were available and were therefore included in
the analysis. The median duration of efavirenz exposure in this group
was 1.1 months (range 0.2–3 months).
Whole blood was provided by the KompNet Cohort. In this prospective
multicentre, Germany-wide cohort, semi-annual follow-up visits are
documented, and clinical and demographic data are collected. EDTA
samples are taken at enrolment and 3 years afterwards; serum
samples are collected at every follow-up visit. Demographic and clinical
data were collected on age, gender, weight, height, adherence (evalu-
ated through pharmacy reports), ethnicity and qualitative smoking
status.32 Ethical approval was granted by the ethics committee of the
Ruhr-Universita¨t Bochum, Germany, and local ethics committee approval
and informed consent were obtained at each site.
Genotyping
Total genomic DNA was isolated using the QIAamp DNA mini kit accord-
ing to the manufacturer’s instructions. Following extraction, purity was
assessed by comparing the A260 and A280 ratio. DNA was quantified
using the PicoGreenw dsDNA Quantitation Reagent (Molecular Probes,
CA, USA) and normalized to 20 ng/mL. For CYP2B6, pre-amplification
was first conducted to discriminate from the CYP2B6 pseudogene
(CYP2B7) by modification of previously reported methods.11 Genotyping
for CYP2B6 (516GT), CYP2A6 (*9B), UGT2B7 (735AG and 802TC),
CAR (540CT) and PXR (44477TC, 63396CT and 69789AG)
was then performed by real-time PCR allelic discrimination using stan-
dard methodology (958C for 15 min, followed by 40 cycles of 958C for
15 s and 608C for 1 min) in a DNA Engine Opticonw 2 system (MJ
Research Inc., USA). For CYP2B6 516GT (rs3745274), CYP2A6*9B
(rs8192726), CAR 540CT (rs2307424), PXR 44477TC (rs1523130)
and PXR 7635AG (rs6785049), Applied Biosystems pre-validated
assays were utilized. The assay IDs were C__7817765_60,
C__29560333_20, C__25746794_20, C__9152783_20 and
C__29280426_10, respectively. For UGT2B7 735AG (rs28365062) the
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forward primer, reverse primer, A probe and G probe were 5′-CCTAAAG-
TAATTATCTTGTGTCATCCACCTT-3′, 5′-CGTCAGCTTTCCCCATTGTCT-3′, 5′-
ACCCACTACATTATCTGT-VIC and 5′-CCCACTACGTTATCTGT-FAM, respect-
ively. For UGT2B7 802TC (rs7439366) the forward primer, reverse
primer, C probe and T probe were 5′-CTGACGTATGGCTTATTCGAAACTC-3′,
5′-TGGAGTCCTCCAACAAAATCAACAT-3′, 5′-AGTGGATGAGGAAACTT-VIC
and 5′-AGAGTGGATAAGGAAACTT-FAM, respectively. For PXR 63396CT
(rs2472677) the forward primer, reverse primer, C probe and T probe
were 5′-GCACAAACATTTTCAATTTCAATGAAGTTCA-3′, 5′-CATTCGGAAGACT-
TATTCTATTCCTGTCT-3′, 5′-CCATATTTTTTCTGATTAAA-VIC and 5′-CCATA
TTTTTTTTGATTAAA-FAM, respectively.
Statistical analysis
All data are given as frequency number (percentage), unless otherwise
stated. Genotypes were tested for Hardy–Weinberg equilibrium by x2
test of observed versus predicted (from allele frequency) genotype
frequencies. Statistical significance was assessed using the x2 test,
Cramer’s V-test or the linear by linear test for differences in qualitative
variables. Univariate and multivariate associations were assessed with
SPSS v16 (SPSS Inc., Chicago, IL, USA) using backward logistic regression.
Continuous variables are expressed as median [interquartile range (IQR)].
A statistical trend was defined as a P value ,0.1. Statistical significance
was set at P,0.05.
Results
This was a cohort study and all patients were recruited between
1 January 2006 and 1 October 2009. Two hundred and forty-two
patients, who were on stable efavirenz-containing HAART for
≥3 months, were included in the control group and 131 patients
were included in the early discontinuation group (discontinuation
of efavirenz-containing HAART within 3 months). Treatment was
discontinued for unknown reasons in 55 patients (42%), for self-
reported CNS-related side effects in 72 cases (55%), virological
failure in 1 case (1%) and elevated liver enzymes or other toxici-
ties in 4 cases (3%). No documented cases of depression were
encountered in these patients. The baseline characteristics of
the patients entered in the study are presented in Table 1.
The backbone therapy was comparable between the discon-
tinuation group and the control group. Preferential nucleoside
reverse transcriptase inhibitor (NRTI)-based backbone therapies
consisting either of tenofovir/emtricitabine or lamivudine/zidovu-
dine were used. The remaining patients were receiving alterna-
tive backbone or NRTI-free therapies. Within the early
discontinuation group, 42 of 131 patients were taking
lamivudine/zidovudine (or zidovudine) (32%) and 59 of 131
patients were taking tenofovir/emtricitabine (45%). Within the
control group, 63 of 242 patients were taking lamivudine/zidovu-
dine (26%) and 114 of 242 patients were receiving tenofovir/
emtricitabine (47%).
Association of demographics and backbone with early
(<3 months) treatment discontinuation
A higher proportion of white patients (39.2%; 109 out of 278) dis-
continued efavirenz-containing HAART within 3 months compared
with black patients (23.2%; 22 out of 95; P¼0.005). Smokers
exhibited a lower frequency of discontinuation (30.9%; 73 out of
236) compared with non-smokers (42.3%; 58 out of 137;
P¼0.026). No other associations (P,0.05) or trends (P,0.10)
were evident with demographic factors, such as age, sex,
weight, height or body mass index (BMI), even when stratified
for ethnicity. Two hundred and seventy-eight patients out of 373
had zidovudine, zidovudine/lamivudine or tenofovir/emtricitabine
as backbone therapy. The frequency of zidovudine/lamivudine (or
zidovudine) administration did not differ between patients who
discontinued (32%; 42 out of 131) and patients who were stable
on efavirenz (26%; 63 out of 242; P¼0.21). Similarly, the frequency
of tenofovir/emtricitabine administration did not differ between
patients who discontinued (45%; 59 out of 131) and patients
who were stable on efavirenz (47%; 114 out of 242; P¼0.71).
Allele frequencies according to ethnicity
The frequencies of the allelic variants in white and black patients
are summarized in Table 2. Differences in the frequencies of the
variant alleles between ethnicity groups (black ethnicity as refer-
ence) were evident for CAR rs2307424CT [odds ratio
(OR)¼2.69; P¼0.0001], CYP2B6 516GT (OR¼0.73; P¼0.087),
CYP2B6 983TC (OR¼0; NA), UGT2B7 802TC (OR¼2.4;
P¼0.0001), PXR 7635AG (OR¼0.14; P¼0.0001), PXR
44477TC (OR¼7.38; P¼0.0001) and PXR 63396CT
(OR¼1.77; P¼0.009).
Association of genetic factors with early (<3 months)
treatment discontinuation
When considering the entire population, CYP2B6 516GT was
statistically associated with early (,3 months) treatment
Table 1. Baseline characteristics of patients with stable efavirenz therapy and with early treatment discontinuation of efavirenz
On therapy .3 months On therapy ,3 months Total
Number of patients 242 131 373
Male gender 189 104 293 (78.6%)
White ethnicity 169 109 278 (74.5%)
Median age, years (IQR) 45 (40–51) 47 (41–53) 46 (26–82)
Median BMI, kg/m2 (IQR) 23.5 (20.5–27.5) 23.5 (20.5–28) 24 (21–28)
Smoking 163 (67.4%) 73 (55.7%) 236 (63.3%)
Median years since diagnosis (range) 6 (1–12) 6 (1–12) 6 (1–12)
Viral load, copies/mL (range) ,50 (,50–8×105) 325 (,50–1×106) ,50 (,50–1×106)
CD4 count, cells/mm3 (range) 449 (12–3233) 325 (0–1260) 407 (0–3233)
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discontinuation. The discontinuation rate was 33.5% (57 out of
170) in the 516GG group compared with 32.5% (55 out of 169)
in the 516GT group and 44.1% (15 out of 34) in the 516TT group
(P¼0.03). Patients characterized by T homozygosity had a
higher probability of early treatment discontinuation (55.9%
versus 33%; P¼0.008). A trend towards a higher frequency of dis-
continuation among patients characterized by CAR rs2307424CC
was also observed, with 38.9% (74 out of 190) of CC patients
versus 30% (54 out of 180) of CT/TT patients discontinuing
therapy before three months (P¼0.071; CAR genotype data
were unavailable for 3 patients). Patients with the TT genotype
for PXR 63396CT had a trend towards a higher frequency of dis-
continuation (41.5%; 51 out 123) compared with patients with
the CT/CC genotype (32%; 80 out of 250; P¼0.072). Similarly,
for UGT2B7 802TC, patients with the TC or CC genotype had a
trend towards higher frequency of discontinuation (37.5%; 101
out of 269) compared with patients with the TT genotype
(28.2%; 29 out of 103; P¼0.089; the UGT2B7 802 genotype was
unavailable for 1 patient). No association (P,0.05) or trend
(P,0.10) was observed for other polymorphisms.
When considering only white patients (n¼278), patients with
CYP2B6 516TT had a higher discontinuation rate (58.3%; 14 out
of 24) compared with patients with CYP2B6 516GG/GT (95 out of
254 patients; P¼0.045). Moreover, white patients with CAR
rs2307424CC had a frequency of early discontinuation of
46.3% (56 out of 121) versus 32.5% (50 out of 154) for CT/TT
patients (P¼0.019). In black patients, the CYP2B6 516TT geno-
type was associated with a higher discontinuation rate (50%;
5 out of 10) than CYP2B6 516GG/GT (20%; 17 out of 85;
P¼0.033). No other associations (P,0.05) or trends (P,0.10)
were evident in either white or black patients.
Multivariate analysis by binary logistic regression
Multivariate logistic regression in the entire cohort confirmed the
independent association of CYP2B6 516 and CAR rs2307424 gen-
otypes with early (,3 months) treatment discontinuation. In
addition to these genetic factors, ethnicity and smoking status
were also identified as independent predictors. As shown in
Table 3, the following parameters were independently associated
with treatment discontinuation: CYP2B6 516TT [OR¼2.81;
95% confidence interval (CI)¼1.34–5.9; P¼0.006]; CAR
rs2307424CC (OR¼1.92; 95% CI¼1.2–3.07; P¼0.007); black
ethnicity (OR¼0.27; 95% CI¼0.14–0.50; P¼0.0001); and
smoking status (OR¼0.45; 95% CI¼0.28–0.74; P¼0.002).
Table 2. Allele frequencies in patients, considering ethnicity
Polymorphism
Variant allele in
white patients
(%)
Variant allele in
black patients
(%) OR P value
CYP2B6 516GT 167/556 (30%) 70/190 (37%) 0.73 0.087
CYP2B6 983TC 0/556 (0%) 8/190 (4%) NA NA
CAR rs2307424CT 180/550 (32.7%) 29/190 (15%) 2.69 0.0001
PXR 44477TC 329/556 (59.1%) 30/190 (15.7%) 7.38 0.0001
PXR 63396CT 339/556 (60.9%) 89/190 (46.8%) 1.77 0.009
PXR 7635AG 237/556 (42.6%) 158/188 (84%) 0.14 0.0001
CYP2A6*9B 40/556 (7.8%) 8/190 (4.2%) 1.78 0.17
UGT2B7 735AG 69/556 (12.4%) 31/190 (16.3%) 0.68 0.101
UGT2B7 802TC 296/556 (53.2%) 61/188 (32.4%) 2.4 0.0001
NA, not applicable.
Table 3. Univariate and multivariate backward logistic regression for the identification of factors associated with
early treatment discontinuation of efavirenz
Covariate
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Gender (female) 0.92 (0.55–1.56) 0.77 —
Ethnicity (black) 0.47 (0.27–0.80) 0.05 0.27 (0.14–0.50) 0.0001
Age (years) 1 (0.99–1) 0.25 —
Height (cm) 0.99 (0.97–1.01) 0.57
Weight (kg) 0.99 (0.98–1.01) 0.58
Smoking (non-smoker) 0.61 (0.39–0.94) 0.03 0.45 (0.28–0.74) 0.002
CYP2B6 516TT 2.56 (1.25–5.2) 0.01 2.81 (1.34–5.90) 0.006
CYP2B6 983C carrier 0.25 (0.031–2.12) 0.21 —
CAR rs2307424CC 1.49 (0.96–2.3) 0.07 1.92 (1.20–3.07) 0.007
PXR 63396C carrier 0.66 (0.43–1.04) 0.07 ND 0.112
CYP2A6*9B carrier 1.4 (0.75–2.65) 0.29
UGT2B7 735G carrier 0.75 (0.45–1.25) 0.28
UGT2B7 802C carrier 1.53 (0.93–2.5) 0.09 ND 0.22
ND, not done.
Rows with a significant P value (P,0.05) in the multivariate analysis are shown in bold.
Constant of the final multivariate model¼0.74; P¼0.21.
Measure of goodness of fit was conducted using the Hosmer–Lemeshow test: x2¼4.8; P¼0.56.
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Composite analysis for genetic and demographic
risk factors
To further confirm the association of these two polymorphisms
with early discontinuation, the CYP2B6 516T and CAR
rs2307424C alleles were classified as discontinuation-associated
alleles. As shown in Figure 1(a), the number of high
discontinuation-associated alleles correlated with the rate of
early discontinuation. The rate of treatment discontinuation
was 25% (4 out of 16) for patients with no discontinuation-
associated alleles, 29.6% (24 out of 81) for patients with one
discontinuation-associated allele, 32.4% (48 out of 148) for
patients with two alleles, 39.4% (43 out of 109) for patients
with three alleles and 56.2% (9 out of 16) for patients with
four alleles (P¼0.023; CAR genotype data were unavailable for
3 patients).
As shown in Figure 1(b), the number of early discontinuation
risk factors harboured by a patient [including CYP2B6 and CAR
genetics (with each allele counting as one risk factor), ethnicity,
and smoking status] was associated with early discontinuation.
The rate of early treatment discontinuation was 0% (n¼1) for
patients with no risk factors, 16.7% (3 out of 18) for patients
with one risk factor, 23% (16 out of 69) for patients with two
risk factors, 31% (45 out of 145) for patients with three risk
factors, 43.9% (43 out of 98) for patients with four risk factors,
51.4% (19 out of 37) for patients with five risk factors and
100% (n¼2) for patients with six risk factors (P¼0.0001; CAR
genotype data were unavailable for 3 patients).
Discussion
Several studies have described an elevated frequency of CNS side
effects in patients treated with efavirenz-based regimens,
leading to treatment discontinuation primarily in the first week
of treatment.3,5 – 7 Interindividual variability in genes involved in
the metabolism and disposition of efavirenz may influence the
onset of side effects and, therefore, therapy discontinuation.
CYP2B6 516 has been identified as a major predictor of efavirenz
plasma concentrations,12 – 19 and a correlation between the
frequency of CNS side effects in white patients and slow-
metabolizer genotypes (CYP2B6 516TT and 983TT) was recently
described.33 In the current cohort, TT homozygosity for the
CYP2B6 516GT polymorphism was independently associated
with early treatment discontinuation.
A novel association between a CAR polymorphism
(rs2307424) and plasma efavirenz concentrations was recently
reported by some of the investigators involved in the present
study.31 The discontinuation data presented here extend these
findings to a clinical phenotype, showing significant association
of the CC genotype with early treatment discontinuation. These
findings strengthen the role of CAR in efavirenz disposition and
pharmacokinetics, presumably through its role in the regulation
of CYP2B6.
A genetic composite of these two polymorphisms (CYP2B6
516CT and CAR rs2307424) was assessed and patients with
more discontinuation-associated alleles (also the same as the
high concentration-associated alleles31) had a higher rate of dis-
continuation. This finding reinforces the hypothesis that early
treatment discontinuation is associated with higher plasma con-
centrations. However, it must be noted that plasma efavirenz
concentrations are higher in black patients than in white
patients,34 yet treatment discontinuation rates appear to be
lower in black patients.35 In the present study, white patients
had a higher frequency of early discontinuation than black
patients. Furthermore, the frequency of CYP2B6 and CAR alleles
associated with higher plasma efavirenz concentrations are
more frequent in black patients. We hypothesize that this appar-
ent paradox may be explained by interethnic variability in other
unknown genes involved in the aetiology of CNS toxicity.
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Figure 1. Bar chart showing the percentage of patients discontinuing
treatment within 3 months and (a) number of discontinuation-
associated alleles (CYP2B6 516T and CAR rs2307424C) and (b) number
of discontinuation-associated risk factors (CYP2B6 516T and CAR
rs2307424C, white ethnicity, and smoking).
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Smoking status was also identified as being independently
associated with early treatment discontinuation. We previously
reported a trend towards an association between smoking and
efavirenz plasma concentrations in the German Competence
Network for HIV/AIDS19 and in a Chilean cohort.31 Interestingly,
nicotine has previously been shown to activate nuclear receptors
such as PXR and CAR,36 and induction of CYP2B6 has been
described.37 Furthermore, nicotine and efavirenz have an
overlapping elimination pathway, both being metabolized by
CYP2B6 and CYP2A6, providing another putative mechanism for
the interaction.38 Nicotine exposure has also been shown to
influence blood–brain barrier permeability in vivo39,40 and may
therefore have an effect on efavirenz diffusion in the CNS,
independently of effects on pharmacokinetics.
It must be noted that a major limitation of the current study
is that the reasons for early discontinuation were not known for
42% of the cohort. However, of those discontinuing therapy for a
known reason, 94.7% discontinued due to CNS toxicity. Other
reasons for early treatment discontinuation (e.g. virological
failure) usually lead to later (.3 months) discontinuation or
modification of therapy. For this reason, it seems likely that in
the majority of patients the reason for the treatment discontinu-
ation was CNS toxicity. Moreover, the reported associations were
also present when univariate logistic analysis was conducted for
patients who discontinued due to known CNS toxicity (n¼72):
CAR rs2307424CC (OR¼1.86; P¼0.037); CYP2B6 516TT
(OR¼2.1; P¼0.122); and black ethnicity (OR¼0.42; P¼0.013).
A potential additional limitation of this study is that no infor-
mation was collected with respect to their adherence to
medication.
In conclusion, our findings indicate that genetic variability in
genes involved in the metabolism and disposition of efavirenz
are determinants of early (,3 months) treatment discontinu-
ation. These data provide evidence that smoking status may
be associated with discontinuation. In vitro studies to identify
the mechanisms underpinning these associations and to identify
toxicological targets in the brain are now warranted.
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